NEW YORK--(BUSINESS WIRE)--July 17, 2006--INNOVIVE Pharmaceuticals Inc., a biopharmaceutical company headquartered in Manhattan, announced today that the first two patients have been enrolled and treated in a Phase I trial investigating compound INNO-406 in imatinib-resistant or intolerant Philadelphia positive leukemias.
